Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 10/20 | 0.42 |
| ▸ | CA1 | P00915 | 9/20 | 0.42 |
| ▸ | MMP1 | P03956 | 3/20 | 0.34 |
| ▸ | MMP2 | P08253 | 3/20 | 0.34 |
| ▸ | MMP9 | P14780 | 3/20 | 0.34 |
| ▸ | MMP8 | P22894 | 3/20 | 0.34 |
| ▸ | MMP13 | P45452 | 3/20 | 0.34 |
| ▸ | F2 | P00734 | 4/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2357198 | 0.92 | CA2 (0.38) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL1551405 | 0.86 | CA2 (0.40) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL22117313 | 0.81 | CA2 (0.39) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL286439 | 0.80 | CA2 (0.46) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL1758440 | 0.79 | CA2 (0.45) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL75966 | 0.79 | CA2 (0.45) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL977331 | 0.78 | CA2 (0.34) | CA2CA1 | |
| SCHEMBL25298036 | 0.77 | CA2 (0.44) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL3027542 | 0.77 | CA2 (0.44) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL15827020 | 0.77 | CA2 (0.44) | CA2CA1MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113195674-A | Hydrofluoroolefins and methods of use thereof | 3M创新有限公司 | 2021-07-30 | — | — | CN | disclosed |
| WO-2020128964-A2 | HYDROFLUOROOLEFINS AND METHODS OF USING SAME | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2020-06-25 | — | — | WO | disclosed |
| EP-2349967-B1 | METHODS OF MAKING FLUORINATED ETHERS, FLUORINATED ETHERS, AND USES THEREOF | 3M INNOVATIVE PROPERTIES CO (US) | 2016-03-23 | — | — | EP | disclosed |
| EP-2250700-B1 | REDOX SHUTTLES FOR HIGH VOLTAGE CATHODES | 3M INNOVATIVE PROPERTIES CO (US) | 2014-09-17 | — | — | EP | disclosed |
| EP-2313365-B1 | AQUEOUS METHODS FOR MAKING FLUORINATED SULFONATE ESTERS | 3M INNOVATIVE PROPERTIES CO (US) | 2013-11-06 | — | — | EP | disclosed |
| US-8350094-B2 | Methods of making fluorinated ethers, fluorinated ethers, and uses thereof | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2496658-A2 | METHODS OF USING HYDROFLUOROETHERS AS HEAT TRANSFER FLUIDS | 3M Innovative Properties Company (US) | 2012-09-12 | — | — | EP | disclosed |
| US-8261560-B2 | Methods of using hydrofluoroethers as heat transfer fluids | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-09-11 | — | — | US | disclosed |
| US-8129412-B2 | Hydantoin derivatives useful as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| US-8101302-B2 | Redox shuttles for high voltage cathodes | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
| US-20100108934-A1 | METHODS OF MAKING FLUORINATED ETHERS, FLUORINATED ETHERS, AND USES THEREOF | 3M INNOVATIVE PROPERTIES COMPANY | 2010-05-06 | — | — | US | disclosed |
| US-20100016624-A1 | AQUEOUS METHODS FOR MAKING FLUORINATED SULFONATE ESTERS | 3M INNOVATIVE PROPERTIES COMPANY | 2010-01-21 | — | — | US | disclosed |
| US-20090286162-A1 | REDOX SHUTTLES FOR HIGH VOLTAGE CATHODES | 3M INNOVATIVE PROPERTIES COMPANY | 2009-11-19 | — | — | US | disclosed |
| WO-2009102604-A1 | REDOX SHUTTLES FOR HIGH VOLTAGE CATHODES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2009-08-20 | — | — | WO | disclosed |
| EP-1828166-B1 | HYDANTOIN DERIVATIVES USEFUL AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-07-22 | — | — | EP | disclosed |
| US-20080280950-A1 | Hydantoin Derivatives Useful as Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | disclosed |
| EP-1828166-A1 | HYDANTOIN DERIVATIVES USEFUL AS METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006064218-A1 | HYDANTOIN DERIVATIVES USEFUL AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| US-6768025-B2 | FOR CONTROLLING BROADLEAF AND GRASS WEEDS IN CROPS | AVENTIS CROPSCIENCE GMBH (DE) | 2004-07-27 | — | — | US | disclosed |
| US-20030060651-A1 | Benzoylcyclohexanedione derivatives and their use as herbicides | BAYER CROPSCIENCE GMBH (DE) | 2003-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280950-A1 | Hydantoin Derivatives Useful as Metalloproteinase Inhibitors | MMP3, MMP9, MMP2 | CA2 130/4885CA1 236/4885MMP1 9/4885 |
| US-20030060651-A1 | Benzoylcyclohexanedione derivatives and their use as herbicides | DDT, CBR3, CBR1 | CA2 336/4885CA1 1232/4885MMP1 3058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.